125 related articles for article (PubMed ID: 16180161)
1. Drug therapy in HIV infection--fourth international congress. 8-12 November 1998, Glasgow, Scotland.
Wainberg MA
IDrugs; 1999 Jan; 2(1):18-9. PubMed ID: 16180161
[TBL] [Abstract][Full Text] [Related]
2. Continuing Progress in the Chess Game of AIDS Treatment.
Jack D
Drug News Perspect; 2002 Dec; 15(10):681-684. PubMed ID: 12677254
[TBL] [Abstract][Full Text] [Related]
3. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
4. Antiviral Research - 15th International Conference. 17-21 March 2002, Prague, Czech Republic.
Esté JA
IDrugs; 2002 May; 5(5):385-7. PubMed ID: 15570449
[TBL] [Abstract][Full Text] [Related]
5. TDM: the key to more effective HIV treatment?
Jack D
Drug News Perspect; 2000 Dec; 13(10):622-7. PubMed ID: 12879133
[TBL] [Abstract][Full Text] [Related]
6. Aiming for quality as well as quantity.
Jack DB
Drug News Perspect; 1998 Dec; 11(10):653-7. PubMed ID: 15616635
[TBL] [Abstract][Full Text] [Related]
7. Raltegravir: the first HIV integrase inhibitor.
Cocohoba J; Dong BJ
Clin Ther; 2008 Oct; 30(10):1747-65. PubMed ID: 19014832
[TBL] [Abstract][Full Text] [Related]
8. Gene therapy and immunotherapy.
McKinnon C
IDrugs; 1999 Jul; 2(7):620-3. PubMed ID: 16127624
[TBL] [Abstract][Full Text] [Related]
9. HIV Drug Resistance and Treatment Strategies - Fourth International Workshop.
Este J
IDrugs; 2000 Sep; 3(9):1032-5. PubMed ID: 16049862
[TBL] [Abstract][Full Text] [Related]
10. Long-term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study.
Gathe JC; Wood R; Sanne I; DeJesus E; Schürmann D; Gladysz A; Garris C; Givens N; Elston R; Yeo J
Clin Ther; 2006 May; 28(5):745-54. PubMed ID: 16861096
[TBL] [Abstract][Full Text] [Related]
11. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
Panel de expertos de Gesida y Plan Nacional sobre el Sida
Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
[TBL] [Abstract][Full Text] [Related]
12. American Society of Gene Therapy--second annual meeting. 9-13 June 1999, Washington DC, USA.
Palmer K
IDrugs; 1999 Aug; 2(8):741-4. PubMed ID: 16127643
[TBL] [Abstract][Full Text] [Related]
13. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel.
Hirsch MS; Günthard HF; Schapiro JM; Brun-Vézinet F; Clotet B; Hammer SM; Johnson VA; Kuritzkes DR; Mellors JW; Pillay D; Yeni PG; Jacobsen DM; Richman DD;
Top HIV Med; 2008; 16(3):266-85. PubMed ID: 19856548
[TBL] [Abstract][Full Text] [Related]
14. Perspectives on antiviral drug development.
Wainberg MA
Antiviral Res; 2009 Jan; 81(1):1-5. PubMed ID: 18948140
[TBL] [Abstract][Full Text] [Related]
15. Overcoming resistance to existing therapies in HIV-infected patients: the role of new antiretroviral drugs.
Perno CF; Moyle G; Tsoukas C; Ratanasuwan W; Gatell J; Schechter M
J Med Virol; 2008 Apr; 80(4):565-76. PubMed ID: 18297706
[TBL] [Abstract][Full Text] [Related]
16. [Viral drug resistance].
Dudman SG; Stene-Johansen K; Vik IS
Tidsskr Nor Laegeforen; 2008 Nov; 128(22):2597-600. PubMed ID: 19023374
[TBL] [Abstract][Full Text] [Related]
17. The impacts of current antiretroviral therapy regimens on Chinese AIDS patients and their implications for HIV-1 drug resistance mutation.
Zhang M; Han XX; Cui WG; Jia MH; Meng XD; Xing AH; Wu YH; Yang YY; Lu CM; Hu QH; Dai D; Zhang ZN; Shang H
Jpn J Infect Dis; 2008 Sep; 61(5):361-5. PubMed ID: 18806342
[TBL] [Abstract][Full Text] [Related]
18. HIV research in Australia: linking basic research findings with clinical and public health outcomes.
Lewin SR; Kaldor JM; Cooper DA
Retrovirology; 2006 Dec; 3():86. PubMed ID: 17140433
[TBL] [Abstract][Full Text] [Related]
19. Drug-sparing regimens for HIV combination therapy: benefits predicted for "drug coasting".
Krakovska O; Wahl LM
Bull Math Biol; 2007 Nov; 69(8):2627-47. PubMed ID: 17578648
[TBL] [Abstract][Full Text] [Related]
20. HIV-1 reverse transcriptase inhibitor resistance mutations and fitness: a view from the clinic and ex vivo.
Martinez-Picado J; Martínez MA
Virus Res; 2008 Jun; 134(1-2):104-23. PubMed ID: 18289713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
